Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses

Research output: Contribution to journalReview article

139 Citations (Scopus)

Abstract

Phase I clinical trials have shown that pure human butyrylcholinesterase (BChE) is safe when administered to humans. A potential therapeutic use of BChE is for prevention of nerve agent toxicity. A recombinant mutant of BChE that rapidly inactivates cocaine is being developed as a treatment to help recovering cocaine addicts avoid relapse into drug taking. These clinical applications rely on knowledge of the structure, stability, and properties of BChE, information that is reviewed here. Gene therapy with a vector that sustains expression for a year from a single injection is a promising method for delivering therapeutic quantities of BChE.

Original languageEnglish (US)
Pages (from-to)34-46
Number of pages13
JournalPharmacology and Therapeutics
Volume148
DOIs
StatePublished - Apr 2015

Fingerprint

Butyrylcholinesterase
Genetic Structures
Therapeutic Uses
Cocaine
Clinical Trials, Phase I
Genetic Therapy
Recurrence
Injections
Therapeutics
Pharmaceutical Preparations

Keywords

  • Butyrylcholinesterase
  • Clinical use
  • Cocaine
  • Genetic variants
  • Nerve agent

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{1a7661f00b234e778a3bbc7bc87a9099,
title = "Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses",
abstract = "Phase I clinical trials have shown that pure human butyrylcholinesterase (BChE) is safe when administered to humans. A potential therapeutic use of BChE is for prevention of nerve agent toxicity. A recombinant mutant of BChE that rapidly inactivates cocaine is being developed as a treatment to help recovering cocaine addicts avoid relapse into drug taking. These clinical applications rely on knowledge of the structure, stability, and properties of BChE, information that is reviewed here. Gene therapy with a vector that sustains expression for a year from a single injection is a promising method for delivering therapeutic quantities of BChE.",
keywords = "Butyrylcholinesterase, Clinical use, Cocaine, Genetic variants, Nerve agent",
author = "Oksana Lockridge",
year = "2015",
month = "4",
doi = "10.1016/j.pharmthera.2014.11.011",
language = "English (US)",
volume = "148",
pages = "34--46",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses

AU - Lockridge, Oksana

PY - 2015/4

Y1 - 2015/4

N2 - Phase I clinical trials have shown that pure human butyrylcholinesterase (BChE) is safe when administered to humans. A potential therapeutic use of BChE is for prevention of nerve agent toxicity. A recombinant mutant of BChE that rapidly inactivates cocaine is being developed as a treatment to help recovering cocaine addicts avoid relapse into drug taking. These clinical applications rely on knowledge of the structure, stability, and properties of BChE, information that is reviewed here. Gene therapy with a vector that sustains expression for a year from a single injection is a promising method for delivering therapeutic quantities of BChE.

AB - Phase I clinical trials have shown that pure human butyrylcholinesterase (BChE) is safe when administered to humans. A potential therapeutic use of BChE is for prevention of nerve agent toxicity. A recombinant mutant of BChE that rapidly inactivates cocaine is being developed as a treatment to help recovering cocaine addicts avoid relapse into drug taking. These clinical applications rely on knowledge of the structure, stability, and properties of BChE, information that is reviewed here. Gene therapy with a vector that sustains expression for a year from a single injection is a promising method for delivering therapeutic quantities of BChE.

KW - Butyrylcholinesterase

KW - Clinical use

KW - Cocaine

KW - Genetic variants

KW - Nerve agent

UR - http://www.scopus.com/inward/record.url?scp=84923273015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923273015&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2014.11.011

DO - 10.1016/j.pharmthera.2014.11.011

M3 - Review article

C2 - 25448037

AN - SCOPUS:84923273015

VL - 148

SP - 34

EP - 46

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

ER -